Vifor Pharma AG (LTS:0RPD) Debt-to-Equity : 0.17 (As of Dec. 2021)

View and export this data going back to 2014. Start your Free Trial

What is Vifor Pharma AG Debt-to-Equity?

Vifor Pharma AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was CHF477 Mil. Vifor Pharma AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was CHF110 Mil. Vifor Pharma AG's Total Stockholders Equity for the quarter that ended in Dec. 2021 was CHF3,490 Mil. Vifor Pharma AG's debt to equity for the quarter that ended in Dec. 2021 was 0.17.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vifor Pharma AG's Debt-to-Equity or its related term are showing as below:

LTS:0RPD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.41 Max: 1.28
Current: 0.17

During the past 13 years, the highest Debt-to-Equity Ratio of Vifor Pharma AG was 1.28. The lowest was 0.06. And the median was 0.41.

LTS:0RPD's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.28 vs LTS:0RPD: 0.17

Vifor Pharma AG Debt-to-Equity Historical Data

The historical data trend for Vifor Pharma AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vifor Pharma AG Debt-to-Equity Chart

Vifor Pharma AG Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Equity

Get a 7-Day Free Trial

0.06

0.19

0.17

Vifor Pharma AG Semi-Annual Data
	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
Debt-to-Equity	Get a 7-Day Free Trial															0.19	0.02	0.17	0.02	0.17

Competitive Comparison of Vifor Pharma AG's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vifor Pharma AG's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's Debt-to-Equity falls into.

Vifor Pharma AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vifor Pharma AG's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(477	+	110.1)	/	3489.9
	=	0.17

Vifor Pharma AG's Debt to Equity Ratio for the quarter that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(477	+	110.1)	/	3489.9
	=	0.17

Vifor Pharma AG (LTS:0RPD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vifor Pharma AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vifor Pharma AG (LTS:0RPD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rechenstrasse 37, Saint Gallen, CHE, 9014

Website

https://www.viforpharma.com

Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (LTS:0RPD) Headlines

No Headlines